この組織は、視力喪失の新しい治療法を開発するための取り組みをリードしており、盲目の影響を受けている人々のための革新的な解決策に焦点を当てています。詳細はFightingBlindness.orgをご覧ください。
J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
3 mins • May 15, 2025
Charts
- 171Decreased by 8
'/%3e%3cpath%20d='M74.965,77.269%20C74.795,75.733%2074.283,74.624%2073.259,73.6%20C71.339,71.595%2067.968,70.272%2064,70.272%20C60.032,70.272%2056.661,71.552%2054.741,73.6%20C53.76,74.667%2053.205,75.733%2053.035,77.269%20C52.693,80.256%2052.907,82.816%2053.248,86.955%20C53.589,90.88%2054.229,96.128%2055.04,101.419%20C55.637,105.216%2056.107,107.264%2056.533,108.715%20C57.259,111.104%2059.861,113.152%2064,113.152%20C68.139,113.152%2070.784,111.061%2071.467,108.715%20C71.893,107.264%2072.363,105.216%2072.96,101.419%20C73.771,96.085%2074.411,90.88%2074.752,86.955%20C75.136,82.816%2075.307,80.256%2074.965,77.269%20z'%20fill='%23FFFFFF'%20id='XMLID_657_'/%3e%3cpath%20d='M74.496,55.509%20C74.496,61.312%2069.803,66.005%2064,66.005%20C58.197,66.005%2053.504,61.312%2053.504,55.509%20C53.504,49.707%2058.197,45.013%2064,45.013%20C69.803,45.013%2074.496,49.749%2074.496,55.509%20z'%20fill='%23FFFFFF'%20id='XMLID_655_'/%3e%3cpath%20d='M63.872,14.165%20C39.381,14.251%2019.328,34.133%2018.987,58.624%20C18.731,78.464%2031.403,95.445%2049.109,101.675%20C49.536,101.845%2049.963,101.461%2049.92,101.035%20C49.707,99.499%2049.451,97.963%2049.28,96.427%20C49.195,95.872%2048.853,95.445%2048.384,95.189%20C34.389,89.088%2024.619,75.051%2024.789,58.795%20C25.003,37.461%2042.411,20.096%2063.701,19.925%20C85.504,19.755%20103.296,37.419%20103.296,59.179%20C103.296,75.264%2093.568,89.088%2079.701,95.189%20C79.189,95.403%2078.848,95.872%2078.805,96.427%20C78.592,97.963%2078.379,99.499%2078.165,101.035%20C78.08,101.504%2078.549,101.845%2078.976,101.675%20C96.512,95.531%20109.099,78.805%20109.099,59.179%20C109.013,34.347%2088.747,14.123%2063.872,14.165%20z'%20fill='%23FFFFFF'%20id='XMLID_653_'/%3e%3cpath%20d='M62.848,29.099%20C46.891,29.696%2034.091,42.88%2033.877,58.837%20C33.749,69.333%2038.997,78.635%2047.061,84.139%20C47.445,84.395%2048,84.096%2048,83.627%20C47.872,81.792%2047.872,80.171%2047.957,78.464%20C48,77.909%2047.787,77.397%2047.36,77.013%20C42.453,72.405%2039.467,65.835%2039.637,58.581%20C39.979,45.781%2050.261,35.371%2063.061,34.859%20C76.971,34.304%2088.405,45.483%2088.405,59.221%20C88.405,66.219%2085.419,72.533%2080.683,77.013%20C80.299,77.397%2080.085,77.909%2080.085,78.464%20C80.171,80.128%2080.128,81.749%2080.043,83.584%20C80,84.053%2080.555,84.395%2080.981,84.096%20C88.917,78.677%2094.165,69.504%2094.165,59.179%20C94.208,42.197%2080,28.416%2062.848,29.099%20z'%20fill='%23FFFFFF'%20id='XMLID_651_'/%3e%3c/g%3e%3c/svg%3e)
- 19Decreased by 2
最近のエピソード
May 15, 2025
J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
3 mins
May 13, 2025
ARVO 2025 Highlight: PYC Reports Encouraging Phase 1/2 Clinical Trial Results for its RNA Therapy Targeting RP (PRPF31 Mutations)
5 mins
May 12, 2025
ARVO 2025 Highlight: Atsena’s XLRS Gene Therapy Provides Vision and Structural Improvements in Phase 1/2 Clinical Trial
4 mins
May 9, 2025
ARVO 2025 Highlight: Beacon Reports Encouraging Results for Second Eyes Dosed in Clinical Trial for XLRP Gene Therapy
3 mins
May 9, 2025
Eye on the Cure Podcast | Episode 85: Cindy Elden
29 mins
